Spine BioPharma
-
Spine
Spine BioPharma, Inc. Announces Completion of Enrollment for Phase 3 Clinical Trial of SB-01 to Address Chronic Low Back Pain
NEW YORK, September 24, 2024 –(BUSINESS WIRE)– Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for…
Read More » -
Spine
Spine BioPharma Announces First Patient Treated in U.S. Phase 3 Clinical Study
SB-01 For Injection Offers New Potential Treatment for Patients Sufferingfrom Chronic Low Back Pain NEW YORK, September 7, 2022 – OrthoSpineNews…
Read More » -
Spine
Spine BioPharma Initiating U.S. Phase 3 Clinical Study
SB-01 For Injection Offers New Potential Treatment for Patients Sufferingfrom Chronic Low Back Pain. New York, NY., May 11, 2022…
Read More » -
Financial
Spine BioPharma Completes Series B Financing
Proceeds Will Support Clinical Advancement of SB-01 For Injection for Treatment of Degenerative Disc Disease NEW YORK, March 28, 2022 /PRNewswire/ — Spine BioPharma, Inc.,…
Read More »